Abstract
Pharmacogenomics is a rapidly growing field dedicated to identifying genetic markers that will allow practitioners to identify safe and effective therapy that is tailored to the individual patient. As a result, pharmacogenomic testing has the potential to optimize drug therapy for a variety of disease states. The landmark Sequenced Treatment Alternatives to Relieve Depression trial, commonly known as the STAR*D trial, showed that only a disappointing 30 % of patients experience remission from depression symptoms with their initial trial of antidepressant therapy. Furthermore, other studies have shown that 70 % of patients not remitting after their first medication trial may endure symptoms for months before experiencing relief secondary to drug therapy. In the future it is hoped that advancing pharmacogenomics research will help identify the safest and most effective medication for each patient—not only for the treatment of depression but for other disease states as well. Currently pharmacogenomic testing is not widely implemented; however, this is likely to change as clinicians become increasingly familiar with this field. This chapter will familiarize clinicians with the field of pharmacogenomics by (1) building a simple understanding of how genetic variability can alter drug response, (2) discussing current approaches in pharmacogenomics research, (3) describing helpful resources for practitioners, (4) providing an overview of the clinical application of pharmacogenomics and the associated issue of reimbursement, and (5) reviewing opinions on the future of pharmacogenomics in the clinical setting.
Kristen M. Wiese and Stephanie A. Flowers contributed equally to this work.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Rush AJ, Trivedi MH, Wisniewski SR et al (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917
Trivedi MH, Rush AJ, Wisniewski SR et al (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40
Gelenberg AJ, Freeman MP, Markowitz JC et al (2010) Practice guideline for the treatment of patients with major depressive disorder. Retrieved from: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
Genetics Home Reference, U.S. National Library of Medicine (2015) What is the International HapMap Project? (2014). Retrieved from: http://ghr.nlm.nih.gov/handbook/genomicresearch/hapmap
Redon R, Ishikawa S, Fitch KR et al (2006) Global variation in copy number in the human genome. Nature 444:444–454
Ouahchi K, Lindeman N, Lee C (2006) Copy number variants and pharmacogenomics. Pharmacogenomics 7:25–29
Clayton AH, Montejo AL (2006) Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 67 Suppl 6:33–37
Higgins A, Nash M, Lynch AM (2010) Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthc Patient Saf 2:141–150
Kennedy SH, Rizvi S (2009) Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 29:157–164
Barr CS, Newman TK, Schwandt M et al (2004) Sexual dichotomy of an interaction between early adversity and the serotonin transporter gene promoter variant in rhesus macaques. Proc Natl Acad Sci U S A 101:12358–12363
Strohmaier J, Wüst S, Uher R et al (2011) Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR. World J Biol Psychiatry 12:528–538
Lesch KP, Bengel D, Heils A et al (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527–1531
Gillihan SJ, Rao H, Wang J et al (2010) Serotonin transporter genotype modulates amygdala activity during mood regulation. Soc Cogn Affect Neurosci 5:1–10
Zanardi R, Serretti A, Rossini D et al (2001) Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50:323–330
Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP (2004) Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 9:879–889
Bishop JR, Ellingrod VL, Akroush M et al (2009) The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives. Hum Psychopharmacol 24:207–215
Daly AK (2010) Genome-wide association studies in pharmacogenomics. Nat Rev Genet 11:241–246
Yang TH, Kon M, DeLisi C (2013) Genome-wide association studies. Methods Mol Biol 939:233–251
Hayes B (2013) Overview of statistical methods for genome-wide association studies (GWAS). Methods Mol Biol 1019:149–169
No authors listed (2010) On beyond GWAS. Nat Genet 42:551
Edwards SL, Beesley J, French JD et al (2013) Beyond GWASs: illuminating the dark road from association to function. Am J Hum Genet 93:779–797
Laje G, Perlis RH, Rush AJ et al (2009) Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv 60:1446–1457
McMahon FJ, Buervenich S, Charney D et al (2006) Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78:804–814
Paddock S, Laje G, Charney D et al (2007) Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 164:1181–1188
Lander ES (2011) Initial impact of the sequencing of the human genome. Nature 470:187–197
Bao R, Huang L, Andrade J et al (2014) Review of current methods, applications, and data management for the bioinformatics analysis of whole exome sequencing. Cancer Inform 13:67–82
Rabbani B, Teki M, Mahdieh N (2014) The promise of whole-exome sequencing in medical genetics. J Hum Genet 59:5–15
Wong ML, Dong C, Flores DL et al (2014) Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans. Am J Psychiatry 171:1297–1309
Cirulli ET, Goldstein DB (2010) Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 11:415–425
Yu Y, Wu B, Wu J et al (2012) Exome and whole-genome sequencing as clinical tests: a transformative practice in molecular diagnostics. Clin Chem 58:1507–1509
Ng PC, Kirkness EF (2010) Whole genome sequencing. Methods Mol Biol 628:215–226
Mizzi C, Peters B, Mitropoulou C et al (2014) Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics 15:1223–1234
Sebat J, Lakshmi B, Troge J et al (2004) Large-scale copy number polymorphism in the human genome. Science 305:525–528
Estivill X, Armengol L (2007) Copy number variants and common disorders: filling the gaps and exploring complexity in genome-wide association studies. PLoS Genet 3:1787–1799
Hooli BV, Kovacs-Vajna ZM, Mullin K et al (2014) Rare autosomal copy number variations in early-onset familial Alzheimer’s disease. Mol Psychiatry 19:676–681
Merikangas AK, Segurado R, Cormican P et al (2014) The phenotypic manifestations of rare CNVs in schizophrenia. Schizophr Res 158:255–260
Coe BP, Witherspoon K, Rosenfeld JA et al (2014) Refining analyses of copy number variation identifies specific genes associated with developmental delay. Nat Genet 46:1063–1071
Zhou SF, Liu JP, Lai XS (2009) Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem 16:2661–2805
Hosono N, Kato M, Kiyotani K et al (2009) CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection. Clin Chem 55:1546–1554
National Institutes of Health (2008) DailyMed – CARBAMAZEPINE- carbamazepine tablet CARBAMAZEPINE- carbamazepine tablet, chewable. Retrieved from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c13bc0b8-7900-4ef4-98ed-e1315a08d95d
Ferrell PB, McLeod HL (2008) Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 9:1543–1546
Hung SI, Chung WH, Jee SH et al (2006) Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 16:297–306
U.S. Food and Drug Administration (2013) Postmarket drug safety information for patients and providers – information for healthcare professionals: dangerous or even fatal skin reactions – carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). Retrieved from: http://www.fda.gov/Drugs/DrugSafety/Postmarket.DrugSafetyInformationforPatientsandProviders/ucm124718.htm
PharmGKB. DPWG: Dutch Pharmacogenetics Working Group. Retrieved from: https://www.pharmgkb.org/page/dpwg
PharmGKB. CPIC: clinical pharmacogenetics implementation consortium. Retrieved from: https://www.pharmgkb.org/page/cpic
Hicks JK, Swen JJ, Thorn CF et al (2013) Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93:402–408
National Human Genome Research Institute (2015) Regulation of genetic tests. Retrieved from: http://www.genome.gov/10002335
Centers for Medicare & Medicaid Services (2014) Clinical laboratory improvements amendments (CLIA). Retrieved from: http://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/index.html?redirect=/clia/
Genetics Home Reference, U.S. National Library of Medicine (2014) How can consumers be sure a genetic test is valid and useful? Retrieved from: http://ghr.nlm.nih.gov/handbook/testing/validtest
Robert J, Milligan RJ (2008) Coverage and reimbursement for pharmacogenomic testing. Jurimetrics J 48:137–165
Priority Health (2010) Pharmacogenomic testing. Retrieved from: https://www.priorityhealth.com/provider/manual/auths/~/media/documents/medical-policies/91570.pdf
Crettol S, de Leo J, Hiemke C, Eap CB (2014) Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. Clin Pharmacol Ther 95:254–257
Perlis RH, Patrick A, Smoller JW et al (2009) When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology 34:2227–2236
Santa Clara University (2008) Pharmacogenomics, ethics, and public policy. Retrieved from: http://www.scu.edu/ethics/practicing/focusareas/medical/pharmacogenomics.html
Genetics Home Reference, U.S. National Library of Medicine (2015) The genetic information nondiscrimination act (GINA). (2014). Retrieved from: http://ghr.nlm.nih.gov/spotlight=thegeneticinformationnondiscriminationactgina
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Wiese, K.M., Flowers, S.A., Ellingrod, V.L. (2016). Pharmacogenomics. In: Jann, M., Penzak, S., Cohen, L. (eds) Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Adis, Cham. https://doi.org/10.1007/978-3-319-27883-4_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-27883-4_6
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-27881-0
Online ISBN: 978-3-319-27883-4
eBook Packages: MedicineMedicine (R0)